Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Hamilton Thorne Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Hamilton Thorne wird ein Gewinn- und Umsatzwachstum von 140.8% bzw. 10.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 143.2% pro Jahr wachsen soll.

Wichtige Informationen

129.3%

Wachstumsrate der Gewinne

126.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.8%
Wachstumsrate der Einnahmen	10.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	15 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Aug 15

Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years

Jan 19

Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?

Jan 06

What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?

Dec 24

We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt

Dec 12

Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?

Nov 30

A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

Nov 17

Here's Why Hamilton Thorne (CVE:HTL) Can Manage Its Debt Responsibly

Aug 24

Is Now An Opportune Moment To Examine Hamilton Thorne Ltd. (CVE:HTL)?

Aug 10

At CA$1.43, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

Aug 10

Gewinn- und Umsatzwachstumsprognosen

TSX:HTL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	93	N/A	15	N/A	2
12/31/2025	87	6	11	N/A	5
12/31/2024	80	2	7	11	7
3/31/2024	70	-2	1	5	N/A
12/31/2023	67	-1	0	4	N/A
9/30/2023	65	0	-1	3	N/A
6/30/2023	63	1	1	4	N/A
3/31/2023	61	1	-2	2	N/A
12/31/2022	58	2	-1	2	N/A
9/30/2022	57	2	0	2	N/A
6/30/2022	57	2	0	2	N/A
3/31/2022	55	2	2	4	N/A
12/31/2021	52	2	3	6	N/A
9/30/2021	49	3	6	8	N/A
6/30/2021	46	3	8	10	N/A
3/31/2021	41	2	5	7	N/A
12/31/2020	40	1	4	6	N/A
9/30/2020	38	1	4	6	N/A
6/30/2020	37	1	2	4	N/A
3/31/2020	38	2	4	6	N/A
12/31/2019	35	1	5	6	N/A
9/30/2019	33	3	3	5	N/A
6/30/2019	31	2	3	5	N/A
3/31/2019	30	2	4	5	N/A
12/31/2018	29	3	3	4	N/A
9/30/2018	28	5	3	4	N/A
6/30/2018	28	6	2	3	N/A
3/31/2018	26	6	2	3	N/A
12/31/2017	22	6	N/A	3	N/A
9/30/2017	19	2	N/A	2	N/A
6/30/2017	15	1	N/A	2	N/A
3/31/2017	12	1	N/A	2	N/A
12/31/2016	11	1	N/A	1	N/A
9/30/2016	9	1	N/A	1	N/A
6/30/2016	9	1	N/A	1	N/A
3/31/2016	9	1	N/A	1	N/A
12/31/2015	9	1	N/A	1	N/A
9/30/2015	9	1	N/A	1	N/A
6/30/2015	9	1	N/A	1	N/A
3/31/2015	9	1	N/A	1	N/A
12/31/2014	9	1	N/A	1	N/A
9/30/2014	8	1	N/A	1	N/A
6/30/2014	8	1	N/A	1	N/A
3/31/2014	8	0	N/A	0	N/A
12/31/2013	7	0	N/A	0	N/A
9/30/2013	7	0	N/A	0	N/A
6/30/2013	7	0	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HTL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.1%).

Ertrag vs. Markt: HTL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: HTL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: HTLDie Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (6.9% pro Jahr).

Hohe Wachstumseinnahmen: HTLDie Einnahmen des Unternehmens (10.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HTL in 3 Jahren voraussichtlich hoch sein wird

Hamilton Thorne Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Consensus EPS estimates increase by 80%

Consensus EPS estimates fall by 80%

Consensus EPS estimates fall by 50%

Consensus EPS estimates increase by 17%

Consensus EPS estimates fall by 33%

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hamilton Thorne Ltd. to Report Q1, 2024 Results on May 14, 2024

Hamilton Thorne Ltd., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$0.004 loss per share (vs US$0.013 profit in FY 2022)

Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024

Hamilton Thorne Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024

New major risk - Revenue and earnings growth

Hamilton Thorne Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Hamilton Thorne Ltd. (TSX:HTL) agreed to acquire Gynetics Medical Products N.V. for an enterprise value of €18.3 million.

Consensus EPS estimates increase by 80%

New minor risk - Shareholder dilution

Hamilton Thorne Ltd.(TSXV:HTL) dropped from S&P/TSX Venture Composite Index

Consensus EPS estimates fall by 80%

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.002 profit in 2Q 2022)

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well

Hamilton Thorne Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.004 in 1Q 2022)

Hamilton Thorne Ltd. to Report Q1, 2023 Results on May 15, 2023

Chair, President & CEO exercised options to buy CA$102k worth of stock.

Chair, President & CEO recently sold CA$101k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued

Consensus EPS estimates increase by 17%

Now 20% undervalued after recent price drop

Hamilton Thorne Ltd. Announces Passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer

Now 21% undervalued after recent price drop

Hamilton Thorne Ltd. (TSXV:HTL) agreed to acquire Microptic, S.L.

Consensus EPS estimates fall by 33%

Hamilton Thorne Ltd. Provides Sales Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.001 (vs US$0.002 in 3Q 2021)

High number of new directors

Hamilton Thorne Ltd. to Report Nine Months, 2022 Results on Nov 22, 2022

Consensus EPS estimates fall by 23%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q2, 2022 Results on Aug 23, 2022

Hamilton Thorne Ltd. Announces CFO Changes

Chair, President exercised options to buy CA$86k worth of stock.

Chair, President exercised options to buy CA$886k worth of stock.

Consensus EPS estimates fall by 20%

At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Hamilton Thorne Ltd. to Report Q1, 2022 Results on May 19, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Hamilton Thorne Ltd., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Chair, President exercised options to buy CA$293k worth of stock.

Hamilton Thorne Ltd. to Report Q4, 2021 Results on Apr 07, 2022

Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?

High number of new directors

President recently bought CA$75k worth of stock

President recently sold CA$635k worth of stock

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely

Second quarter 2021 earnings released: EPS US$0.003 (vs US$0.004 loss in 2Q 2020)

Hamilton Thorne Ltd. (TSXV:HTL) acquired IVFTECH ApS and K4 Technology ApS for an enterprise value of approximately DKK 50 million ($8 million).

President exercised options to buy CA$115k worth of stock.

Should You Think About Buying Hamilton Thorne Ltd. (CVE:HTL) Now?

Consensus EPS estimates increase to US$0.028

First quarter 2021 earnings released: EPS US$0.006 (vs US$0.001 in 1Q 2020)

Hamilton Thorne (CVE:HTL) Will Be Hoping To Turn Its Returns On Capital Around

Independent Director recently bought CA$107k worth of stock

Is Hamilton Thorne (CVE:HTL) A Risky Investment?

Full year 2020 earnings released: EPS US$0.007 (vs US$0.006 in FY 2019)

Estimating The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)

When Should You Buy Hamilton Thorne Ltd. (CVE:HTL)?